Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;44(3):774-780.
doi: 10.2337/dc20-2023. Epub 2021 Jan 19.

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study

Lawrence Blonde  1 , Julio Rosenstock  2 , Juan Frias  3 , Andreas L Birkenfeld  4   5 , Elisabeth Niemoeller  6 , Elisabeth Souhami  7 , Chen Ji  8 , Stefano Del Prato  9 , Vanita R Aroda  10   11
Affiliations

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study

Lawrence Blonde et al. Diabetes Care. 2021 Mar.

Abstract

Objective: In the LixiLan-G trial, switching to iGlarLixi, a once-daily titratable fixed-ratio combination of insulin glargine 100 units/mL and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide, improved glucose control in type 2 diabetes uncontrolled with GLP-1 RAs over 26 weeks versus continuing prior GLP-1 RA. A prespecified, 26-week, single-arm extension of LixiLan-G aimed to determine the durability of iGlarLixi efficacy and safety over 52 weeks.

Research design and methods: Participants with type 2 diabetes uncontrolled by GLP-1 RAs (glycated hemoglobin [HbA1c] 7-9% [53-75 mmol/mol]) were initially randomized to switch to iGlarLixi or continue prior GLP-1 RA. Those randomized to iGlarLixi who completed the 26-week primary end point period could continue iGlarLixi open-label treatment over a 26-week extension to assess durability of efficacy and safety.

Results: Glycemic control achieved with iGlarLixi at week 26 (mean HbA1c 6.7% [50 mmol/mol]) was maintained at week 52 (mean HbA1c 6.7% [50 mmol/mol]; mean ± SD change from baseline at week 52: -1.0 ± 0.9% [11 ± 10 mmol/mol]). Proportions of participants reaching HbA1c <7% (53 mmol/mol) with iGlarLixi were similar at week 26 (62%) and 52 (64%), as were those reaching this target without documented symptomatic (<3.0 mmol/L) hypoglycemia (57% and 58%). Safety of iGlarLixi was similar at weeks 26 and 52, with low rates of documented symptomatic hypoglycemia and gastrointestinal events.

Conclusions: The efficacy and safety of iGlarLixi at the end of the 26-week randomized treatment period was maintained over the 26-week extension period in the LixiLan-G trial.

Trial registration: ClinicalTrials.gov NCT02787551.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Glycemic target: HbA1c change from baseline to week 52 (A) and proportion of participants achieving HbA1c <7% (53 mmol/mol) (B) without documented symptomatic (<3.0 mmol/L) hypoglycemia. LS, least squares; No., number.
See this image and copyright information in PMC

References

    1. European Medicines Agency . Suliqua summary of product characteristics, 2019. Accessed 12 February 2020. Available from https://www.ema.europa.eu/en/documents/product-information/suliqua-epar-...
    1. Sanofi . Soliqua US prescribing information, 2019. Accessed 12 February 2020. Available from https://products.sanofi.us/Soliqua100-33/Soliqua100-33.pdf
    1. Blonde L, Rosenstock J, Del Prato S, et al. . Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial. Diabetes Care 2019;42:2108–2116 - PubMed
    1. American Diabetes Association . 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S98–S110 - PubMed
    1. Davies MJ, D’Alessio DA, Fradkin J, et al. . Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669–2701 - PMC - PubMed

Publication types